| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Barrett Esophagus | 62 | 2024 | 334 | 18.300 |
Why?
|
| Esophageal Neoplasms | 58 | 2024 | 356 | 17.410 |
Why?
|
| Adenocarcinoma | 56 | 2024 | 1003 | 13.380 |
Why?
|
| Stomach Neoplasms | 18 | 2024 | 537 | 7.850 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 22 | 2024 | 386 | 7.580 |
Why?
|
| Liver Neoplasms | 32 | 2024 | 1375 | 6.740 |
Why?
|
| Carcinoma, Hepatocellular | 29 | 2024 | 948 | 6.740 |
Why?
|
| Helicobacter Infections | 17 | 2024 | 1251 | 4.690 |
Why?
|
| Precancerous Conditions | 12 | 2023 | 287 | 4.680 |
Why?
|
| Gastroesophageal Reflux | 20 | 2024 | 288 | 4.300 |
Why?
|
| Alcohol Drinking | 11 | 2024 | 336 | 4.290 |
Why?
|
| Risk Factors | 88 | 2024 | 9668 | 3.980 |
Why?
|
| Liver Cirrhosis | 20 | 2024 | 822 | 3.960 |
Why?
|
| Helicobacter pylori | 16 | 2024 | 1309 | 3.700 |
Why?
|
| Obesity | 22 | 2024 | 2082 | 3.020 |
Why?
|
| Middle Aged | 111 | 2024 | 25364 | 3.020 |
Why?
|
| Incidence | 43 | 2024 | 2984 | 2.960 |
Why?
|
| Aged | 88 | 2024 | 18450 | 2.790 |
Why?
|
| Humans | 200 | 2024 | 121682 | 2.510 |
Why?
|
| Colorectal Neoplasms | 11 | 2024 | 558 | 2.500 |
Why?
|
| Male | 129 | 2024 | 59083 | 2.330 |
Why?
|
| Life Style | 7 | 2022 | 391 | 2.200 |
Why?
|
| United States | 45 | 2024 | 10405 | 2.180 |
Why?
|
| Smoking | 11 | 2023 | 1027 | 2.110 |
Why?
|
| Female | 126 | 2024 | 64437 | 2.100 |
Why?
|
| Veterans | 16 | 2023 | 1707 | 1.960 |
Why?
|
| Case-Control Studies | 33 | 2021 | 3221 | 1.920 |
Why?
|
| Adult | 72 | 2024 | 28599 | 1.880 |
Why?
|
| Risk Assessment | 29 | 2024 | 3216 | 1.870 |
Why?
|
| Proton Pump Inhibitors | 9 | 2023 | 252 | 1.840 |
Why?
|
| Mendelian Randomization Analysis | 9 | 2021 | 82 | 1.750 |
Why?
|
| Neoplasms | 8 | 2024 | 2749 | 1.720 |
Why?
|
| Early Detection of Cancer | 7 | 2023 | 326 | 1.700 |
Why?
|
| Cross-Sectional Studies | 24 | 2023 | 3283 | 1.650 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2023 | 229 | 1.560 |
Why?
|
| Metaplasia | 11 | 2022 | 212 | 1.560 |
Why?
|
| Demography | 6 | 2021 | 238 | 1.520 |
Why?
|
| Population Surveillance | 5 | 2022 | 380 | 1.490 |
Why?
|
| Prevalence | 20 | 2022 | 2371 | 1.480 |
Why?
|
| Registries | 17 | 2024 | 1350 | 1.450 |
Why?
|
| Aged, 80 and over | 26 | 2024 | 6095 | 1.450 |
Why?
|
| Histamine H2 Antagonists | 3 | 2019 | 49 | 1.430 |
Why?
|
| Esophagoscopy | 6 | 2024 | 150 | 1.400 |
Why?
|
| Odds Ratio | 15 | 2021 | 1226 | 1.390 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2019 | 710 | 1.360 |
Why?
|
| Carcinoma, Squamous Cell | 6 | 2022 | 649 | 1.290 |
Why?
|
| Healthcare Disparities | 3 | 2024 | 403 | 1.270 |
Why?
|
| Socioeconomic Factors | 9 | 2024 | 857 | 1.250 |
Why?
|
| Stomach | 2 | 2022 | 272 | 1.250 |
Why?
|
| Polymorphism, Single Nucleotide | 13 | 2022 | 2577 | 1.250 |
Why?
|
| Veterans Health | 2 | 2020 | 171 | 1.240 |
Why?
|
| Logistic Models | 16 | 2021 | 1756 | 1.230 |
Why?
|
| Texas | 17 | 2024 | 3521 | 1.200 |
Why?
|
| Body Mass Index | 9 | 2024 | 1454 | 1.190 |
Why?
|
| Rectal Neoplasms | 2 | 2021 | 76 | 1.170 |
Why?
|
| Models, Statistical | 3 | 2016 | 445 | 1.150 |
Why?
|
| Intestines | 3 | 2021 | 571 | 1.130 |
Why?
|
| Colonic Polyps | 3 | 2023 | 78 | 1.120 |
Why?
|
| Decision Support Techniques | 5 | 2020 | 277 | 1.110 |
Why?
|
| Nutrition Surveys | 7 | 2022 | 275 | 1.110 |
Why?
|
| Mexican Americans | 2 | 2018 | 197 | 1.070 |
Why?
|
| Pancreatic Neoplasms | 2 | 2024 | 688 | 1.060 |
Why?
|
| Body Height | 4 | 2018 | 205 | 1.050 |
Why?
|
| Colonic Neoplasms | 2 | 2021 | 247 | 1.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 4 | 2018 | 303 | 1.030 |
Why?
|
| Global Health | 5 | 2022 | 554 | 1.030 |
Why?
|
| Cohort Studies | 21 | 2024 | 4632 | 1.030 |
Why?
|
| Disease Progression | 12 | 2024 | 1968 | 1.020 |
Why?
|
| Health Status Disparities | 5 | 2024 | 213 | 1.020 |
Why?
|
| Elasticity Imaging Techniques | 3 | 2024 | 125 | 1.020 |
Why?
|
| Anthropometry | 2 | 2017 | 189 | 0.980 |
Why?
|
| Aspirin | 3 | 2016 | 219 | 0.950 |
Why?
|
| Lipase | 2 | 2024 | 87 | 0.950 |
Why?
|
| Hepatitis C | 3 | 2023 | 368 | 0.940 |
Why?
|
| Endoscopy, Digestive System | 6 | 2018 | 153 | 0.940 |
Why?
|
| Esophagogastric Junction | 2 | 2016 | 26 | 0.940 |
Why?
|
| Predictive Value of Tests | 12 | 2024 | 2058 | 0.900 |
Why?
|
| Young Adult | 24 | 2024 | 8702 | 0.900 |
Why?
|
| Hepatitis C, Chronic | 2 | 2018 | 319 | 0.890 |
Why?
|
| Genetic Predisposition to Disease | 12 | 2024 | 3066 | 0.880 |
Why?
|
| Leptin | 2 | 2015 | 209 | 0.870 |
Why?
|
| SEER Program | 6 | 2024 | 192 | 0.840 |
Why?
|
| Prognosis | 13 | 2024 | 4474 | 0.830 |
Why?
|
| Endoscopy, Gastrointestinal | 7 | 2023 | 237 | 0.820 |
Why?
|
| Gallbladder Neoplasms | 1 | 2022 | 13 | 0.820 |
Why?
|
| Primary Health Care | 4 | 2024 | 747 | 0.790 |
Why?
|
| Minority Groups | 2 | 2020 | 251 | 0.770 |
Why?
|
| Tobacco Smoking | 1 | 2021 | 18 | 0.770 |
Why?
|
| Retrospective Studies | 26 | 2024 | 15582 | 0.740 |
Why?
|
| Point-of-Care Testing | 1 | 2020 | 27 | 0.710 |
Why?
|
| United States Department of Veterans Affairs | 5 | 2021 | 642 | 0.680 |
Why?
|
| Electric Impedance | 2 | 2017 | 56 | 0.680 |
Why?
|
| Stomach Diseases | 1 | 2020 | 56 | 0.680 |
Why?
|
| Electronic Health Records | 4 | 2024 | 687 | 0.670 |
Why?
|
| Obesity, Abdominal | 2 | 2016 | 35 | 0.650 |
Why?
|
| Liver Transplantation | 3 | 2024 | 1030 | 0.640 |
Why?
|
| Diet | 5 | 2023 | 1096 | 0.630 |
Why?
|
| Endoscopic Mucosal Resection | 3 | 2024 | 72 | 0.590 |
Why?
|
| Virus Diseases | 1 | 2020 | 279 | 0.590 |
Why?
|
| Klatskin Tumor | 1 | 2017 | 5 | 0.590 |
Why?
|
| Follow-Up Studies | 8 | 2024 | 4981 | 0.590 |
Why?
|
| Fibrosis | 4 | 2024 | 422 | 0.570 |
Why?
|
| Membrane Proteins | 2 | 2024 | 1524 | 0.570 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2017 | 99 | 0.560 |
Why?
|
| Prospective Studies | 16 | 2024 | 5895 | 0.560 |
Why?
|
| Surgical Procedures, Operative | 1 | 2018 | 182 | 0.540 |
Why?
|
| Multivariate Analysis | 7 | 2021 | 1395 | 0.540 |
Why?
|
| Overweight | 3 | 2023 | 339 | 0.540 |
Why?
|
| Metabolic Syndrome | 2 | 2021 | 322 | 0.530 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2016 | 77 | 0.530 |
Why?
|
| Acculturation | 1 | 2016 | 68 | 0.530 |
Why?
|
| Bile Duct Neoplasms | 1 | 2017 | 112 | 0.530 |
Why?
|
| Cholangiocarcinoma | 1 | 2017 | 110 | 0.530 |
Why?
|
| Tea | 1 | 2015 | 15 | 0.530 |
Why?
|
| Genome-Wide Association Study | 12 | 2022 | 1632 | 0.530 |
Why?
|
| Environmental Exposure | 1 | 2018 | 214 | 0.520 |
Why?
|
| Coffee | 1 | 2015 | 23 | 0.520 |
Why?
|
| Cold Temperature | 1 | 2015 | 81 | 0.510 |
Why?
|
| Survival Analysis | 6 | 2019 | 1459 | 0.510 |
Why?
|
| Hot Temperature | 1 | 2015 | 135 | 0.510 |
Why?
|
| Exercise | 4 | 2022 | 786 | 0.500 |
Why?
|
| Skin Neoplasms | 2 | 2020 | 801 | 0.500 |
Why?
|
| Serum | 1 | 2015 | 45 | 0.500 |
Why?
|
| Adipokines | 1 | 2015 | 58 | 0.490 |
Why?
|
| Adiponectin | 1 | 2015 | 109 | 0.490 |
Why?
|
| Cost of Illness | 1 | 2016 | 236 | 0.490 |
Why?
|
| Europe | 6 | 2024 | 366 | 0.490 |
Why?
|
| Chemoprevention | 1 | 2015 | 60 | 0.480 |
Why?
|
| Models, Genetic | 1 | 2017 | 748 | 0.480 |
Why?
|
| Biopsy | 4 | 2022 | 1242 | 0.470 |
Why?
|
| Adipose Tissue | 1 | 2017 | 446 | 0.460 |
Why?
|
| Melatonin | 1 | 2014 | 25 | 0.460 |
Why?
|
| Australia | 7 | 2017 | 140 | 0.460 |
Why?
|
| Pregnancy Outcome | 2 | 2014 | 592 | 0.460 |
Why?
|
| Birth Weight | 1 | 2015 | 333 | 0.450 |
Why?
|
| Survival Rate | 4 | 2024 | 1983 | 0.450 |
Why?
|
| Phospholipases A2, Calcium-Independent | 2 | 2024 | 13 | 0.440 |
Why?
|
| Alanine Transaminase | 3 | 2020 | 152 | 0.440 |
Why?
|
| Acyltransferases | 2 | 2024 | 46 | 0.440 |
Why?
|
| Proportional Hazards Models | 6 | 2024 | 1284 | 0.440 |
Why?
|
| Age Factors | 7 | 2020 | 2770 | 0.440 |
Why?
|
| Melanoma | 1 | 2020 | 840 | 0.430 |
Why?
|
| ROC Curve | 5 | 2021 | 550 | 0.420 |
Why?
|
| Risk | 7 | 2020 | 743 | 0.420 |
Why?
|
| Algorithms | 3 | 2022 | 1572 | 0.420 |
Why?
|
| Gastrointestinal Diseases | 1 | 2016 | 334 | 0.420 |
Why?
|
| Liver Diseases, Alcoholic | 2 | 2023 | 57 | 0.410 |
Why?
|
| Adiposity | 1 | 2014 | 181 | 0.410 |
Why?
|
| Age Distribution | 4 | 2022 | 399 | 0.410 |
Why?
|
| Liver Diseases | 1 | 2016 | 382 | 0.410 |
Why?
|
| Inflammation | 2 | 2018 | 1393 | 0.400 |
Why?
|
| Sex Factors | 8 | 2020 | 1226 | 0.400 |
Why?
|
| Premature Birth | 1 | 2015 | 380 | 0.380 |
Why?
|
| HIV Infections | 3 | 2019 | 1863 | 0.380 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2011 | 68 | 0.370 |
Why?
|
| Acetaminophen | 1 | 2011 | 92 | 0.360 |
Why?
|
| Time Factors | 7 | 2020 | 5994 | 0.350 |
Why?
|
| Guideline Adherence | 2 | 2024 | 376 | 0.350 |
Why?
|
| Pregnant Women | 1 | 2011 | 149 | 0.350 |
Why?
|
| Insulin | 1 | 2015 | 1190 | 0.350 |
Why?
|
| Multiple Myeloma | 2 | 2022 | 172 | 0.350 |
Why?
|
| Neoplasm Staging | 3 | 2021 | 1224 | 0.350 |
Why?
|
| Colonoscopy | 3 | 2023 | 238 | 0.340 |
Why?
|
| United Kingdom | 6 | 2019 | 189 | 0.340 |
Why?
|
| Biomarkers | 2 | 2020 | 2918 | 0.330 |
Why?
|
| Cytokines | 2 | 2016 | 1274 | 0.320 |
Why?
|
| Area Under Curve | 4 | 2021 | 305 | 0.320 |
Why?
|
| Adolescent | 14 | 2021 | 18869 | 0.310 |
Why?
|
| Vitamin D | 2 | 2021 | 157 | 0.310 |
Why?
|
| Meta-Analysis as Topic | 3 | 2024 | 151 | 0.290 |
Why?
|
| Databases, Factual | 4 | 2021 | 1138 | 0.290 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2018 | 118 | 0.290 |
Why?
|
| Aspartate Aminotransferases | 2 | 2016 | 76 | 0.270 |
Why?
|
| Severity of Illness Index | 3 | 2023 | 2789 | 0.270 |
Why?
|
| Confidence Intervals | 2 | 2019 | 275 | 0.260 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2024 | 1115 | 0.250 |
Why?
|
| Germ-Line Mutation | 2 | 2018 | 312 | 0.250 |
Why?
|
| Hyperplasia | 2 | 2022 | 214 | 0.250 |
Why?
|
| Gastritis | 2 | 2019 | 371 | 0.240 |
Why?
|
| Recurrence | 3 | 2018 | 1386 | 0.240 |
Why?
|
| Ablation Techniques | 2 | 2024 | 32 | 0.240 |
Why?
|
| Residence Characteristics | 2 | 2024 | 265 | 0.240 |
Why?
|
| Genotype | 3 | 2022 | 2534 | 0.240 |
Why?
|
| Rural Population | 2 | 2024 | 241 | 0.220 |
Why?
|
| Biomarkers, Tumor | 3 | 2020 | 1421 | 0.220 |
Why?
|
| Diet, Mediterranean | 1 | 2023 | 10 | 0.220 |
Why?
|
| Gastrectomy | 1 | 2024 | 87 | 0.220 |
Why?
|
| Ovarian Neoplasms | 2 | 2018 | 415 | 0.220 |
Why?
|
| Mortality | 1 | 2024 | 221 | 0.210 |
Why?
|
| Frailty | 1 | 2024 | 97 | 0.210 |
Why?
|
| Arsenic | 1 | 2023 | 46 | 0.210 |
Why?
|
| Bile Acids and Salts | 1 | 2024 | 236 | 0.200 |
Why?
|
| Natural Language Processing | 1 | 2022 | 61 | 0.200 |
Why?
|
| Hospitals, Veterans | 3 | 2018 | 353 | 0.200 |
Why?
|
| Social Class | 1 | 2023 | 180 | 0.200 |
Why?
|
| Esophagitis, Peptic | 1 | 2021 | 33 | 0.190 |
Why?
|
| Hysterectomy | 1 | 2023 | 181 | 0.190 |
Why?
|
| Gastric Mucosa | 2 | 2022 | 480 | 0.190 |
Why?
|
| Waist-Hip Ratio | 3 | 2019 | 49 | 0.190 |
Why?
|
| Cerebral Hemorrhage | 1 | 2002 | 141 | 0.190 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2021 | 1199 | 0.190 |
Why?
|
| Physical Fitness | 1 | 2021 | 88 | 0.190 |
Why?
|
| Principal Component Analysis | 2 | 2018 | 140 | 0.180 |
Why?
|
| Medicare | 2 | 2022 | 417 | 0.180 |
Why?
|
| Reproducibility of Results | 4 | 2020 | 2793 | 0.180 |
Why?
|
| North America | 2 | 2019 | 233 | 0.180 |
Why?
|
| Hepacivirus | 1 | 2022 | 242 | 0.180 |
Why?
|
| Diet Records | 1 | 2020 | 72 | 0.180 |
Why?
|
| Dietary Fiber | 1 | 2020 | 73 | 0.170 |
Why?
|
| Hepatitis B | 1 | 2021 | 161 | 0.170 |
Why?
|
| Nutritive Value | 1 | 2020 | 91 | 0.170 |
Why?
|
| Gene-Environment Interaction | 2 | 2017 | 118 | 0.170 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2020 | 77 | 0.170 |
Why?
|
| Dietary Carbohydrates | 1 | 2020 | 114 | 0.170 |
Why?
|
| Cholesterol | 1 | 2002 | 517 | 0.170 |
Why?
|
| Safety-net Providers | 1 | 2020 | 41 | 0.170 |
Why?
|
| Practice Guidelines as Topic | 2 | 2024 | 1238 | 0.170 |
Why?
|
| Chromosome Mapping | 1 | 2022 | 1068 | 0.170 |
Why?
|
| Surveys and Questionnaires | 3 | 2023 | 3619 | 0.170 |
Why?
|
| Gastroenterology | 2 | 2024 | 189 | 0.170 |
Why?
|
| Genetic Pleiotropy | 1 | 2018 | 24 | 0.160 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2019 | 231 | 0.160 |
Why?
|
| Fruit | 1 | 2020 | 215 | 0.160 |
Why?
|
| Self Report | 2 | 2018 | 492 | 0.160 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2019 | 138 | 0.160 |
Why?
|
| Quantitative Trait Loci | 1 | 2019 | 266 | 0.160 |
Why?
|
| Sensitivity and Specificity | 3 | 2019 | 2007 | 0.150 |
Why?
|
| Gastric Acid | 1 | 2018 | 50 | 0.150 |
Why?
|
| Capsule Endoscopy | 1 | 2018 | 20 | 0.150 |
Why?
|
| Epidemiological Monitoring | 1 | 2018 | 59 | 0.150 |
Why?
|
| Sarcoma, Kaposi | 1 | 2019 | 120 | 0.150 |
Why?
|
| Feeding Behavior | 1 | 2023 | 676 | 0.150 |
Why?
|
| Energy Intake | 1 | 2020 | 447 | 0.150 |
Why?
|
| Omeprazole | 1 | 2018 | 98 | 0.150 |
Why?
|
| Sex Distribution | 2 | 2016 | 283 | 0.150 |
Why?
|
| Software | 1 | 2022 | 671 | 0.150 |
Why?
|
| Regression Analysis | 1 | 2019 | 755 | 0.150 |
Why?
|
| Molecular Epidemiology | 1 | 2017 | 157 | 0.140 |
Why?
|
| Multifactorial Inheritance | 1 | 2017 | 134 | 0.140 |
Why?
|
| Liver | 2 | 2021 | 1850 | 0.140 |
Why?
|
| Work Schedule Tolerance | 1 | 2016 | 37 | 0.140 |
Why?
|
| Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 1 | 2016 | 16 | 0.140 |
Why?
|
| Cause of Death | 1 | 2019 | 448 | 0.140 |
Why?
|
| Interferon-gamma Release Tests | 1 | 2017 | 85 | 0.140 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2017 | 47 | 0.140 |
Why?
|
| Receptor, Melanocortin, Type 4 | 1 | 2016 | 27 | 0.140 |
Why?
|
| Protective Factors | 1 | 2016 | 82 | 0.130 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 791 | 0.130 |
Why?
|
| Quality Indicators, Health Care | 1 | 2018 | 212 | 0.130 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2018 | 220 | 0.130 |
Why?
|
| Duodenum | 1 | 2016 | 98 | 0.130 |
Why?
|
| Glutathione Transferase | 1 | 2016 | 149 | 0.130 |
Why?
|
| Keratinocytes | 1 | 2016 | 60 | 0.130 |
Why?
|
| Comorbidity | 1 | 2021 | 1474 | 0.130 |
Why?
|
| Celiac Disease | 1 | 2016 | 70 | 0.130 |
Why?
|
| Hepatitis B, Chronic | 1 | 2016 | 84 | 0.130 |
Why?
|
| Catheter Ablation | 1 | 2018 | 226 | 0.130 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2016 | 69 | 0.130 |
Why?
|
| Patient Compliance | 1 | 2018 | 464 | 0.120 |
Why?
|
| Geography | 3 | 2020 | 112 | 0.120 |
Why?
|
| Schistosoma japonicum | 2 | 2012 | 4 | 0.120 |
Why?
|
| Apgar Score | 1 | 2014 | 48 | 0.120 |
Why?
|
| Treatment Outcome | 3 | 2024 | 11684 | 0.120 |
Why?
|
| Alcoholic Beverages | 1 | 2014 | 18 | 0.120 |
Why?
|
| Hernia, Hiatal | 1 | 2014 | 53 | 0.120 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 603 | 0.120 |
Why?
|
| Diagnostic Errors | 1 | 2017 | 314 | 0.110 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2017 | 306 | 0.110 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2017 | 455 | 0.110 |
Why?
|
| Postoperative Complications | 1 | 2024 | 2867 | 0.110 |
Why?
|
| Policy Making | 1 | 2013 | 57 | 0.110 |
Why?
|
| Cohort Effect | 1 | 2012 | 5 | 0.100 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2015 | 278 | 0.100 |
Why?
|
| Sweden | 1 | 2012 | 33 | 0.100 |
Why?
|
| Hypertension | 1 | 2021 | 1264 | 0.100 |
Why?
|
| Chi-Square Distribution | 1 | 2014 | 570 | 0.100 |
Why?
|
| Anticholesteremic Agents | 1 | 2015 | 230 | 0.100 |
Why?
|
| Body Weight | 1 | 2016 | 964 | 0.100 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2015 | 191 | 0.100 |
Why?
|
| Schistosomiasis | 1 | 2012 | 49 | 0.100 |
Why?
|
| New South Wales | 1 | 2011 | 7 | 0.100 |
Why?
|
| Ultrasonography | 1 | 2016 | 935 | 0.100 |
Why?
|
| Antiviral Agents | 1 | 2016 | 731 | 0.100 |
Why?
|
| Age of Onset | 1 | 2013 | 569 | 0.100 |
Why?
|
| Beer | 1 | 2011 | 4 | 0.100 |
Why?
|
| Schistosomiasis japonica | 1 | 2011 | 4 | 0.100 |
Why?
|
| Phenotype | 2 | 2018 | 4198 | 0.100 |
Why?
|
| Wine | 1 | 2011 | 15 | 0.090 |
Why?
|
| Cattle Diseases | 1 | 2011 | 19 | 0.090 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 840 | 0.090 |
Why?
|
| Patient Selection | 1 | 2014 | 647 | 0.090 |
Why?
|
| Tuberculosis | 1 | 2017 | 566 | 0.090 |
Why?
|
| Computer Terminals | 1 | 2010 | 2 | 0.090 |
Why?
|
| Pregnancy | 2 | 2014 | 7071 | 0.090 |
Why?
|
| Sex Characteristics | 2 | 2023 | 301 | 0.090 |
Why?
|
| Mutation | 1 | 2024 | 5738 | 0.090 |
Why?
|
| Clinical Competence | 1 | 2017 | 969 | 0.090 |
Why?
|
| Antibodies, Bacterial | 1 | 2011 | 384 | 0.080 |
Why?
|
| Metabolic Diseases | 1 | 2010 | 127 | 0.080 |
Why?
|
| Adolescent Behavior | 1 | 2010 | 171 | 0.080 |
Why?
|
| Decision Making | 1 | 2013 | 651 | 0.070 |
Why?
|
| Evidence-Based Medicine | 2 | 2024 | 598 | 0.070 |
Why?
|
| Child | 5 | 2021 | 24030 | 0.060 |
Why?
|
| Sarcopenia | 1 | 2024 | 37 | 0.060 |
Why?
|
| Muscular Diseases | 1 | 2024 | 103 | 0.060 |
Why?
|
| Geography, Medical | 1 | 2023 | 16 | 0.060 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2023 | 35 | 0.060 |
Why?
|
| Fast Foods | 1 | 2023 | 31 | 0.060 |
Why?
|
| Phospholipases | 1 | 2022 | 8 | 0.050 |
Why?
|
| Cluster Analysis | 1 | 2023 | 385 | 0.050 |
Why?
|
| End Stage Liver Disease | 1 | 2024 | 178 | 0.050 |
Why?
|
| Clinical Decision-Making | 1 | 2024 | 262 | 0.050 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2022 | 41 | 0.050 |
Why?
|
| Fatty Liver | 1 | 2023 | 182 | 0.050 |
Why?
|
| Sentinel Surveillance | 2 | 2012 | 19 | 0.050 |
Why?
|
| Praziquantel | 2 | 2012 | 11 | 0.050 |
Why?
|
| Anthelmintics | 2 | 2012 | 52 | 0.050 |
Why?
|
| Sunburn | 1 | 2021 | 5 | 0.050 |
Why?
|
| Specialties, Nursing | 1 | 2001 | 3 | 0.050 |
Why?
|
| Pigmentation | 1 | 2021 | 36 | 0.050 |
Why?
|
| Cholagogues and Choleretics | 1 | 2020 | 25 | 0.050 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2020 | 37 | 0.040 |
Why?
|
| Cattle | 2 | 2012 | 556 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2023 | 479 | 0.040 |
Why?
|
| Observer Variation | 1 | 2001 | 297 | 0.040 |
Why?
|
| Serine Endopeptidases | 1 | 2020 | 176 | 0.040 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2019 | 84 | 0.040 |
Why?
|
| Medically Uninsured | 1 | 2020 | 73 | 0.040 |
Why?
|
| Eye Proteins | 1 | 2020 | 215 | 0.040 |
Why?
|
| Health Behavior | 1 | 2022 | 378 | 0.040 |
Why?
|
| Neurology | 1 | 2001 | 108 | 0.040 |
Why?
|
| Linkage Disequilibrium | 1 | 2019 | 305 | 0.040 |
Why?
|
| Genetic Loci | 1 | 2020 | 334 | 0.040 |
Why?
|
| Causality | 1 | 2018 | 78 | 0.040 |
Why?
|
| International Classification of Diseases | 1 | 2019 | 88 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 2024 | 923 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2019 | 178 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 295 | 0.040 |
Why?
|
| Morbidity | 1 | 2019 | 239 | 0.040 |
Why?
|
| DNA, Neoplasm | 1 | 2019 | 303 | 0.040 |
Why?
|
| Weight Loss | 1 | 2021 | 441 | 0.040 |
Why?
|
| Cardiovascular Diseases | 1 | 2010 | 1809 | 0.040 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2019 | 122 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 2012 | 1275 | 0.040 |
Why?
|
| Aftercare | 1 | 2018 | 144 | 0.040 |
Why?
|
| Learning Curve | 1 | 2017 | 49 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 974 | 0.040 |
Why?
|
| Hemoglobins | 1 | 2018 | 298 | 0.030 |
Why?
|
| RNA-Binding Proteins | 1 | 2020 | 567 | 0.030 |
Why?
|
| Queensland | 1 | 2016 | 1 | 0.030 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2016 | 88 | 0.030 |
Why?
|
| Medical History Taking | 1 | 2016 | 106 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2018 | 605 | 0.030 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2018 | 133 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 409 | 0.030 |
Why?
|
| Hepatitis B virus | 1 | 2016 | 141 | 0.030 |
Why?
|
| Elective Surgical Procedures | 1 | 2016 | 148 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2016 | 231 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 1032 | 0.030 |
Why?
|
| HLA Antigens | 1 | 2016 | 243 | 0.030 |
Why?
|
| Colon | 1 | 2017 | 347 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2002 | 1976 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2016 | 598 | 0.030 |
Why?
|
| Child, Preschool | 3 | 2018 | 13765 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2017 | 268 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2016 | 460 | 0.030 |
Why?
|
| Stroke | 1 | 2001 | 945 | 0.030 |
Why?
|
| Mass Screening | 1 | 2018 | 776 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 1710 | 0.020 |
Why?
|
| Drug Therapy | 1 | 2012 | 87 | 0.020 |
Why?
|
| Alleles | 1 | 2016 | 1587 | 0.020 |
Why?
|
| China | 1 | 2012 | 227 | 0.020 |
Why?
|
| Taiwan | 1 | 2011 | 31 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2016 | 787 | 0.020 |
Why?
|
| Waist Circumference | 1 | 2010 | 84 | 0.020 |
Why?
|
| Puberty | 1 | 2010 | 94 | 0.020 |
Why?
|
| Television | 1 | 2010 | 70 | 0.020 |
Why?
|
| Animals | 3 | 2018 | 33661 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2018 | 8081 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2016 | 4505 | 0.010 |
Why?
|
| Infant | 1 | 2018 | 12268 | 0.010 |
Why?
|
| Community Health Services | 1 | 2001 | 90 | 0.010 |
Why?
|